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 1 
Impact of a pilot multidisciplinary clinic for frequent attending elderly patients on deprescribing  2 
 3 
Abstract 4 
 5 
Objective 6 
Multi-morbidity and associated polypharmacy are risk factors for hospital readmission. The Targeting 7 
Hospitalization Risks in Vulnerable Elders (THRIVE) clinic is a novel multi-disciplinary outpatient clinic 8 
to improve transitions of care and decrease readmission risk for older medical patients with frequent 9 
hospital admissions.  This pilot study examined the impact of the THRIVE model on medication count, 10 
tablet load and potentially inappropriate medicines (PIMs).  11 
Methods 12 
Participants with frequent medical admissions were referred within 2 weeks of discharge from hospital 13 
and assessed at baseline, 4 and 12 weeks by the THRIVE team. A thorough reconciliation of all 14 
medications was collaboratively performed by a clinical pharmacist and a physician. Optimising 15 
medications, including deprescribing, was in collaboration with the participants’ general practitioner.  16 
The complete medication history of each patient was retrospectively compared by an independent 17 
assessor at baseline and after the 12-week clinic, comparing total number of regular medications, tablet 18 
load and PIMs (measured using the STOPP tool).   19 
Results 20 
All 17 participants attending the pilot THRIVE clinic were included. At 12 weeks there was a significant 21 
reduction in mean medication count [14.3 to 11.2 medications (P<0.001)] and mean tablet load [20.5 to 22 
16.9 tablets (P<0.01)]. There was reduction in the total number of PIMs from 38 to 14. Common 23 
medications deprescribed included opioids, tricyclic antidepressants, benzodiazepines and diuretics.  24 
Conclusion 25 
Patients who attended the THRIVE clinic had a significant reduction in medication count and tablet load. 26 
The pilot study demonstrates the feasibility of a multi-disciplinary outpatient clinic to improve 27 
  
 
  
   
2 
prescribing and reduce unwarranted medications in an elderly population. An adequately powered 1 
comparative study would allow assessment of clinical outcomes and costs. 2 
 3 
 4 
 5 
What is known about the topic? 6 
Elderly patients are prone to polypharmacy. The identification and deprescribing of potentially 7 
inappropriate medications is effective in reducing adverse drug events in this population. However, acute 8 
hospitalisation is not always the ideal setting to initiate deprescribing. 9 
 10 
What does the paper add? 11 
Intensive multidisciplinary outpatient care for frequently readmitted patients optimises their medication 12 
management plan and helps reduce the use of unwarranted medications. 13 
 14 
What are the implications for practitioners?  15 
Effective deprescribing in elderly patients can be achieved post hospital discharge using a 16 
multidisciplinary collaborative model, but costs and clinical benefits require further investigation. 17 
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Main text 1 
Introduction 2 
 3 
Prescribing medications in the elderly population is challenging. Complex disease states and age-related 4 
decline in physiological function affect the pharmacokinetics and pharmacodynamics of many drugs 
1
. As 5 
such, the necessary balance between maintaining effectiveness while minimizing medicine-related harm 6 
can be difficult to achieve. Adverse drug-related events (ADEs) are common in elderly people and are an 7 
important cause of hospitalizations and readmissions.
2-4
 Polypharmacy is common in older patients due to 8 
the accumulation of complex co-morbidities, 
5, 6
 and increases the risk of ADEs.
3, 6
 Polypharmacy is also 9 
associated with inappropriate medication use, 
7
 defined as the use of drugs that have a greater risk of 10 
causing an ADE than the production of a perceived benefit.
8
 This includes medications which lack a clear 11 
evidence-based indication, carry a high risk of an ADE in the recipient, or are not cost-effective.
9
 12 
Interventions designed to reduce inappropriate prescribing can safely reduce polypharmacy, and have the 13 
potential to improve patient outcomes and reduce healthcare costs. However, these outcome benefits have 14 
yet to be clearly demonstrated in well-designed trials. 
6, 10-12
  15 
 16 
“Deprescribing” has emerged as a term to describe the rational withdrawal (including discontinuing or 17 
tapering) of inappropriate medications to reduce polypharmacy.
10, 12
 Several systematic approaches to 18 
deprescribing have been proposed, 
10, 13, 14
 and have recently been summarized into a five step patient-19 
centred deprescribing process.
15
 These steps include obtaining a comprehensive medication history; 20 
indentifying potentially inappropriate medications (PIMs); prioritizing medications for cessation; 21 
initiating safe withdrawal; and providing monitoring and support to the patient. A central component of 22 
deprescribing is to identify PIMs. This requires an extensive review of a patient’s individual medications 23 
in which clinicians consider the goals of care, treatment targets, and the potential risks and benefits of 24 
medications, including drug-drug and drug-disease interactions. This complex task may benefit from a 25 
collaborative approach between physician and pharmacist, particularly for older patients with multi-26 
  
 
  
   
4 
morbidity.
16
 However, such approaches are resource intensive, and may need to be targeted to high-risk 1 
groups. 2 
 3 
Risk factors for polypharmacy and inappropriate prescribing include older patient age and multi-4 
morbidity,
10, 17-19
 higher health care use and recent hospitalization, where multiple prescribers, different 5 
drug formularies (hospital: primary care) and poor communication between providers at transition points 6 
all contribute.
10, 17
 Recent hospitalisation and multi-morbidity are also potent risk factors for hospital 7 
readmission.
2, 20
 The Targeting Hospitalization Risks in Vulnerable Elders (THRIVE) clinic is a novel 8 
multi-disciplinary outpatient service piloted at the Royal Brisbane and Women’s Hospital (RBWH) to 9 
improve transitional care from hospital to home in this high risk group.
21, 22
 We have previously reported 10 
the impact of the pilot service on patient-reported transition quality.
23
 Medication reconciliation and 11 
optimization are recognized as important components of this transition, and collaborative medication 12 
review was a key aim of the service. We hypothesised that patients enrolled in the feasibility pilot would 13 
have rational withdrawal of inappropriate medications (deprescribing). We tested this by undertaking an 14 
independent retrospective review of medication records at clinic entry and 12 week follow-up, comparing 15 
medication count, tablet load and PIMs.   16 
  17 
18 
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 1 
Methods 2 
 3 
Setting and participants 4 
 5 
The feasibility pilot of the THRIVE model was conducted in the general medicine service of a major 6 
metropolitan teaching hospital in Brisbane, Australia between June 2012 and February 2013. Inpatients 7 
aged 60 and older who had had at least one previous unplanned hospitalization in the preceding six-8 
months were identified prospectively by a research nurse. Patients were ineligible if they did not reside in 9 
Brisbane, were discharged to residential care, were palliative, could not consent, or were receiving care 10 
from the hospital’s heart failure service; where comprehensive multidisciplinary intervention already 11 
occurred. Eligible patients were invited to participate if their treating medical team agreed. The study was 12 
approved by the RBWH Human Research Ethics Committee.  13 
 14 
Intervention 15 
  16 
During hospital admission, participants received usual inpatient care, which included medication 17 
reconciliation by a clinical pharmacist at admission and discharge. Participants had an initial clinic visit 18 
within two weeks post-discharge from hospital and were re-assessed at least twice in the following 12 19 
weeks by the THRIVE team. The team consisted of a registered nurse, clinical pharmacist, specialist 20 
physician, physiotherapist and exercise physiologist. The initial visit included structured comprehensive 21 
assessments of patient goals, supports, function, nutrition, mood, medical history and active morbidities. 22 
This informed a plan of care, developed with the patient and communicated promptly to the general 23 
practitioner (GP) and referring inpatient medical team. The plan included medication recommendations, 24 
an individualised exercise plan, review of social supports and referral to additional services if required, 25 
and self-management advice including symptom management and recognition of “red flags”. Progress 26 
was reassessed at the following two visits, aiming to discharge back to primary care by 12 weeks. 27 
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 1 
Pharmaceutical care was consistent with the recently proposed patient-centred deprescribing process.
15
 2 
Patients were encouraged to bring all current medications to their first visit. The clinical pharmacist 3 
obtained a comprehensive medication history using two or more sources such as the community 4 
pharmacy dispensing records, labelling on a compliance aid, hospital discharge or GP letter and 5 
information provided by relative/carers. The pharmacist also identified potential for drug-drug and drug-6 
disease interactions, and identified drugs with potential for harm. 7 
 8 
The physician reviewed all diagnoses and co-morbidities, with attention to medications that did not have 9 
a clear indication, unnecessary duplication, or drugs with potential for harm, as well as underutilized 10 
therapies. The physician and pharmacist then discussed and prioritized potential medications for cessation 11 
or tapering, and new commencement. Recommendations were discussed with the patient, including the 12 
potential benefits and harms, alignment with the patients’ stated goals of care, a recommended reduction 13 
regimen for drugs with recognised potential for adverse withdrawal effects, and time until review. 14 
Handwritten advice was provided in the clinic, including proposed tapering regimens, and the patient 15 
advised to discuss the recommended changes with their GP.  16 
 17 
All recommendations were provided in writing to the patient’s GP within five-days, with telephone calls 18 
from the physician in more complex cases, ensuring their close involvement in the process. The 19 
community pharmacy were also contacted regarding immediate recommendations initiated by the 20 
THRIVE team. At subsequent visits, the clinical pharmacist confirmed any medication changes, and the 21 
physician assessed clinical impact of the changes, and suggested further adjustments as required (for 22 
example, continued tapering, withdrawal of another medication, reinstatement or substitution of a more 23 
appropriate alternative.)    24 
 25 
  
 
  
   
7 
Outcome measures 1 
 2 
PIMs at baseline and 12 weeks were identified retrospectively using the Screening Tool of Older Persons 3 
Prescriptions (STOPP).
24
 This tool consists of explicit criteria for inappropriate prescribing in older 4 
patients, developed by consensus techniques, and has good reliability and predictive validity for adverse 5 
drug events.
8, 17
 The STOPP tool was applied to the reconciled medication list recorded in the clinical 6 
notes at baseline and 12 weeks by an independent assessor who had not been involved in provision of 7 
services, and the number and type of PIMs at each time point recorded. The total number of medications 8 
(medication count) and the total number of doses (tablet load) were calculated. “Medication count” was 9 
defined as all regular, including complementary, medications the patient was taking per day at the time of 10 
assessment and could include inhalers, injections, topical preparations and orally administered drugs. “As 11 
required” (PRN) medications were not included. “Tablet load” was described as the total number of 12 
individual administrations for all regular medications per day. For example, if a patient was taking two 13 
5mg tablets four times a day, the tablet load would equal eight. Patient demographics and clinical data 14 
were collected prospectively by the clinic registered nurse in a standardised format. 15 
 16 
Analysis 17 
 18 
Participant characteristics were summarized with standard descriptive statistics. The Wilcoxon matched 19 
pairs test was used to compare medication and tablet count at the two time points. Number and type of 20 
PIMs were tabulated for each time point and correlation explored between medication count and number 21 
of PIMs at admission to the clinic. 22 
 23 
24 
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 1 
Results 2 
 3 
Of 199 patients screened with a previous admission, 73 were discharged to residential aged care, 46 were 4 
cared for by the local heart failure service, 11 were palliative and 16 had other exclusions leaving 52 5 
eligible. The hospital treating clinical team elected to continue usual care for 24 pat ients, 9 declined and 6 
19 consented, of whom 17 attended the clinic (one readmitted prior to review and died and one failed to 7 
attend).  First clinical review occurred within 2 weeks for 70% and within 28 days for all participants.  8 
 9 
The mean age of the study population (10 male, 7 female) was 77.8 (SD  9.3) years. Median Charlson 10 
comorbidity score was 3 (interquartile range 1-4), and patients frequently had additional symptomatic 11 
comorbidities including osteoporosis (n=9), venous thromboembolic disease and chronic venous 12 
insufficiency (n=5), mental health disorders (n=7), chronic back pain (n=5) and painful peripheral 13 
neuropathies (n=6). All participants had a regular general practitioner whom they attended 2-4 weekly, 14 
and 2 reported having a formal domiciliary medication management review (DMMR) by a consultant 15 
pharmacist in the past. Two participants self-filled a dose administration aid, 2 used an aid packed by a 16 
nurse or accommodation manager, and 6 had an aid packed by their pharmacy.  Eleven reported “never” 17 
missing medication doses, and 6 admitted to “rarely” or “sometimes” missing doses. Participants had had 18 
a median of 20 (interquartile range 10-46) previous admissions to the study hospital, with median 2 19 
admissions in the 6 months prior to the index admission.  20 
 21 
The demographics, medication use and number of PIMs of all 17 patients at the time of first clinic (T0) 22 
and at the time of final clinic (T12) are presented in Table 1. At T0, patients were prescribed a mean of 23 
14.3 (SD  6.1) medications compared to 11.2 (SD  5.1) medications at T12 (P<0.001). There was also a 24 
significant reduction in mean tablet load from 20.5 (SD  9.1) to 16.9 (SD  7.7) (P<0.01). A total of 52 25 
medications were ceased (22% of all medications). 26 
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 1 
Table 1. Description of patients  2 
 3 
Patient 
 # 
Age 
(years) 
Sex Medication 
count 
(T0) 
Medication 
count  
(T12) 
Tablet load 
(T0) 
Tablet load 
(T12) 
PIMs 
(T0) 
PIMs  
(T12) 
1 86 F 16 13 30 24 4 1 
2 79 F 4 5 5 7 0 0 
3 84 M 7 4 15 12 1 1 
4 89 M 20 16 35 25 5 1 
5 73 F 23 11 22 15 8 2 
6 64 M 9 7 8 7 3 1 
7 68 M 16 8 19 15 3 1 
8 75 M 10 11 15 16 0 0 
9 95 F 9 6 9 5 0 0 
10 60 M 18 18 22 22 0 0 
11 88 F 23 13 29 19 2 0 
12 74 F 19 20 24 28 3 3 
13 77 M 8 7 19 16 4 3 
14 73 M 23 21 37 33 2 2 
15 70 F 11 10 14 15 0 0 
16 80 M 12 10 22 11 1 0 
17 80 M 15 11 24 18 2 2 
Total   243 191 349 288 38 14 
 4 
F = female, M = male, PIMs = potentially inappropriate medications, T0 = time of first THRIVE clinic (week 0), T12 = time of 5 
final THRIVE clinic (week 12). 6 
 7 
The number and description of PIMs is shown in Table 2. Twelve participants had at least one PIM 8 
according to STOPP criteria at baseline. As shown in Figure 1, participants on more medications also 9 
tended to have greater numbers of PIMs (r
2
 = 0.27, P=0.035). Clinical interventions led to a 63% decrease 10 
in PIMs as defined by STOPP criteria (38 to 14). At least one PIM was ceased in 8 of the 12 patients with 11 
a PIM at baseline. Medications ceased included tricyclic antidepressants, benzodiazepines, opiates, 12 
phenothiazines and diuretics (Table 2). 13 
 14 
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 1 
 2 
 3 
Figure 1. The total number of potentially inappropriate medications (PIMs) versus medication 4 
count at first clinic (T0)5 
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 1 
Table 2. Description of PIMs successfully desprescribed 2 
 3 
STOPP criteria 
25
 
PIMs at 
T=0 
PIMs at 
T=12 
Cardiovascular system 
   
Loop diuretic for ankle oedema without clinical signs of heart failure 2 1 
Loop diuretic as first line monotherapy for hypertension 1 0 
Thiazide diuretic with a history of gout 1 1 
Beta-blocker in combination with verapamil 1 0 
Diltiazem/verapamil with moderate-severe heart failure 2 1 
Calcium channel blockers with chronic constipation 3 2 
Warfarin for first uncomplicated DVT for longer than 6 month duration 1 0 
 
Central nervous system 
   
Tricyclic antidepressant with cardiac conductive abnormalities 1 0 
Tricyclic antidepressant with constipation 3 1 
Tricyclic antidepressant with an opiate or calcium channel blocker 4 1 
Long-term, long-acting benzodiazepines 4 1 
Phenothiazines in patients with epilepsy 2 0 
SSRIs with a clinically significant history of hyponatraemia 
 1 1 
Gastrointestinal system 
   
PPI for peptic ulcer disease at full therapeutic dose for 8 > weeks 1 1 
 
Analgesic drugs 
   
Regular opiates for > 2 weeks in those with chronic constipation without 
the use of laxatives 1 1 
 
Duplicate drug-class prescriptions 3 1 
   
Drugs adversely affecting individuals prone to falls 
   
Benzodiazepines 3 1 
Neuroleptic Drugs  1 0 
Long-term opiates in those with recurrent falls 
 2 0 
Total STOPP criteria present 38 14 
 4 
PIMs = potentially inappropriate medications, T0 = time of first THRIVE clinic (week 0), T12 = time of final THRIVE clinic 5 
(week 12), PPI = proton pump inhibitor, SSRI = selective serotonin re-uptake inhibitor6 
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Discussion 1 
 2 
We investigated whether collaborative care in a multidisciplinary outpatient clinic would reduce 3 
inappropriate medication use in older patients at high risk of readmission. Our pilot sample was 4 
characterised by prevalent comorbidity and high previous hospital use, and all patients were taking 5 or 5 
more prescribed medicines (i.e. polypharmacy). Seventy percent of patients had at least one PIM at clinic 6 
referral, and PIMs were correlated with the total number of medications (Figure 1). Total medication 7 
count was reduced by 22% (mean 3 medications per patient) and PIMs by 63% by the 12-week follow-up 8 
visit. Medications ceased included those which predispose to cognitive impairment and falls in elders, an 9 
area where there is evidence that drug withdrawal benefits outcomes.
26
 10 
 11 
Inappropriate medication use has been estimated to occur in 35% of community-dwelling elders, 
7, 27
 and 12 
25-56% of hospitalized elders.
8, 16, 17
 Previous studies in older medical or medical/surgical patients report 13 
an average of 7 medications per patient, with 0.3-1 PIMs per patient.
8, 16, 25
 Our selected cohort of 14 
frequently admitted older patients had 14 medications and 2.2 PIMs per patient. In theory, repeated 15 
hospitalization provides an opportunity for medication review and optimization in complex patients. Our 16 
hospital has a well-developed clinical pharmacy service and close senior physician supervision of junior 17 
staff. A recent observational study of frequently admitted medical patients showed that most had 18 
pharmacist-assisted discharge medication reconciliation.
22
 Despite this, we found a high prevalence of 19 
PIMs following discharge. Frequent hospitalizations may be associated with multiple providers, 20 
competing therapeutic priorities and reluctance to question previous ‘expert’ opinion. This might explain 21 
the surprisingly low uptake of DMMR in this high-risk sample, where the GP may have assumed that 22 
frequent physician and pharmacist review in hospital assured optimal prescribing. However, with limited 23 
clinician time, pressure for rapid discharge, an emphasis on the acute pathology, and a lack of continuity 24 
  
 
  
   
13 
with primary care decision making,
13
 acute hospitalization is not an ideal setting to initiate 1 
deprescribing.
28
  2 
 3 
The THRIVE clinic model tested in this feasibility pilot provided a suitable team, setting and systems for 4 
successful deprescribing. Collaboration between a senior physician and pharmacist ensured a 5 
comprehensive, patient-centred assessment and medication plan. Prompt, detailed communication with 6 
the GP and planned follow-up appointments provided support and continuity for monitoring when 7 
decisions were made to withdraw medications. Previous discussions of the deprescribing process, and its 8 
place in the wider medication-use process, have emphasised the central role of the primary care provider 9 
and their relationship with the patient.
13
 However, in patients with complex multi-morbidity such as those 10 
in our pilot, accessing information about previous prescribing decisions and confirmatory information 11 
about co-morbidities can be very challenging. Each patient requires a comprehensive review of old 12 
inpatient and outpatient notes as well as confirmatory data from a variety of sources in the hospital 13 
system and primary care (for example radiology, pathology, biochemical). This process requires 14 
considerable time, expertise and access to information. The involvement of a senior physician and 15 
pharmacist with access to hospital information systems was essential to the identification of PIMs, and 16 
GPs were receptive to suggestions regarding deprescribing. This is consistent with previous studies that 17 
have shown value in multidisciplinary approaches to pharmaceutical care in reducing polypharmacy.
10, 11
  18 
 19 
Not all PIMs were ceased, and more medications were ceased than those identified as PIMs using the 20 
STOPP tool. While tools such as the STOPP tool and Beers’ criteria 29 may help identify common PIMs 21 
in the geriatric population and evaluate the impact of interventions, they are not as comprehensive or 22 
flexible as clinical judgment.
7, 8
 Most actions were deferred to the GP, and delays in actions may have 23 
occurred due to delayed patient attendance, or repackaging of the dose-aid. Patients with multiple PIMs 24 
and those involving drugs with potential adverse drug withdrawal events had phased withdrawal plans, 25 
  
 
  
   
14 
and the outcome tool measured only medication cessation, not dose reduction. Seven patients had an 1 
emergency department presentation during the study, and 6 were readmitted within the first 12 weeks, 2 
reflecting the high utilization in this group and raising the risk of further drug additions. The large 3 
reduction in PIMs in this context is very encouraging.   4 
 5 
Important limitations of this pilot are the small sample size and lack of a control group. This reflects its 6 
nature as a feasibility pilot of a complex intervention, intended to inform design and power calculations 7 
for an intervention study. The pilot clearly enrolled a high-risk group suitable for intervention, and we 8 
have previously reported high patient satisfaction with the quality of transition,
23
 although strict inclusion 9 
criteria (including physician willingness) may have introduced selection bias and reduces generalisability. 10 
Detailed measurement of GP and patient adherence to recommended medication changes was beyond the 11 
scope of the study, but use of multi-source data for the medication histories (patient, community 12 
pharmacy, carer and GP if required) is consistent with best practice and provides a reliable data source for 13 
this study. Finally, the senior physician (AM) and pharmacist (MB) providing the service contributed to 14 
the evaluation design, but the data collection and analysis for this report were undertaken by a senior 15 
pharmacy student who was not involved in service delivery, maintaining objectivity.   16 
 17 
Conclusion 18 
 19 
A collaborative pharmaceutical care model implemented in the early post-hospital period reduced 20 
inappropriate prescribing and medication count in older medical patients with frequent hospital 21 
admissions. The promising findings from this feasibility pilot will inform design of a controlled trial 22 
adequately powered to examine important clinical outcomes.  23 
 24 
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